Amino acid supplement with HMB for muscle loss in liver cirrhosis
Tests an amino acid supplement for muscle loss in people with cirrhosis.
Key facts
- Who runs it
- The Cleveland Clinic
- Where
- Cleveland, United StatesSee the site
- Trial code
- Registry title
- HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis
- Status
- Recruiting
- People taking part
- 24 people, planned
- Started
- 30 Nov 2021
- Expected to end
- 30 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Hydroxy Methyl Butyrate
- Balanced Amino Acids
- Record updated
- 28 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cirrhosis of the liver to test whether an HMB-enriched amino acid supplement helps rebuild lost muscle.
- Age
- 21 Years to 65 Years
- Sex
- All sexes can join.
- Disease stage
- Cirrhosis of the liver with a Child-Pugh score of 5-8 (a score of how well the liver works).
- Earlier treatment
- People taking medicines that change how muscles use protein, or medicines that affect blood clotting, cannot join.
- Biomarker or test result
- INR must not be above 1.7, platelets not below 60,000/ml, serum creatinine not above 2mg/dL (177 µmol/L), and HbA1C not above 7.9mg/dL.
Main reasons for not taking part
- Bleeding in the stomach or gut in the last 3 months
- Active infection or obvious brain confusion from liver disease (overt encephalopathy)
- Kidney failure on dialysis, or advanced heart, lung or kidney disease
- Swelling of the feet, cancer that has spread, or pregnancy
- Recent bowel removal surgery or gastric bypass surgery
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Diagnosis of cirrhosis of the liver
- Child-Pugh score of 5-8
Who cannot take part
- Medications that alter muscle protein metabolism
- Recent bowel resection or gastric bypass surgery,
- Medications that interfere with blood clotting
- Recent gastrointestinal bleeding (<3m)
- Active infection
- Renal failure on dialysis
- Advanced cardiac, lung, kidney disease
- Metastatic cancer
- Uncontrolled diabetes (HbA1C > 7.9mg/dL)
- INR >1.7, platelets <60,000/ml, serum creatinine >2mg/dL
- Overt encephalopathy
- Pedal edema
- Pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 65 years old?
Where in United States
- Cleveland ClinicCleveland, United StatesContact: Annette BellarTaking people
About the trial
What the trial wants to find out
Loss of skeletal muscle mass or sarcopenia is the most common and potentially reversible complication in cirrhosis that increases morbidity and mortality before, during and after liver transplantation. No proven treatments exist for the prevention or reversal of sarcopenia in cirrhosis, primarily because the mechanisms responsible for this are unknown. Based on compelling preliminary studies and those of the co investigator, investigators hypothesize that the mechanism of reduced skeletal muscle mass in cirrhosis is due to a myostatin mediated impaired mTOR (mechanistic target of rapamycin) signaling resulting in reduced protein synthesis and increased autophagy. Investigators further postulate that leucine, a direct stimulant of mTOR, will reverse the impaired mTOR phosphorylation in the skeletal muscle of cirrhotics. The consequent increase in protein synthesis reduced autophagy will result in an increase in skeletal muscle mass. Investigators will test these hypotheses by quantifying the response to acute and long term (3 month) administration of hydroxymethyl butyrate (HMB) enriched essential amino acid compared with an isonitrogenous isocaloric non-essential balanced amino acid mixture (does not stimulate protein synthesis) in cirrhotic patients. Fractional protein synthesis rate (FSR) in skeletal muscle, responses of the molecular regulatory pathways of skeletal muscle protein synthesis, and autophagy flux will be quantified in the acute and long term protocols. Tracer studies using L-[D5]-phenylalanine (Phe) as a primed constant infusion (prime 2µmol.kg-1.hr-1; constant 0.05 µmol.kg-1.hr-1) with and L [ring-D2] tyrosine, forearm plethysmography, and sequential skeletal muscle biopsies (total of 3 per study subject) will be used to quantify these outcomes. Anthropometric, clinical and body composition measures will be additional outcome measures for the long term intervention. Expression of regulatory signaling proteins, myostatin, IGF-1 (insulin like growth factor) , phospho-Akt, phospho-AMPK (activated protein kinase), phospho-mTOR and phospho-p70s6k will be quantified by Western immunoblots. Autophagy flux will be measured by quantifying expression of the autophagosome proteins.
The 2 groups in the trial
- Hydroxy Methyl ButyrateExisting treatment, for comparison
- Balanced Amino Acid MixtureOther group
Treatment: Balanced Amino Acids
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis
- Plain-language title
- Amino acid supplement with HMB for muscle loss in liver cirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05166499, who can take part
- Record updated
- 28 September 2026